Medical News

[ Mismatch Between Global Disease Burden In Youths And Research Devoted To Pediatric Patients ]

Mismatch Between Global Disease Burden In Youths And Research Devoted To Pediatric Patients

Although children are more likely than adults to suffer from many diseases, few clinical trials are being conducted to test drugs in pediatric patients, according to a study presented at the Pediatric Academic Societies (PAS) annual meeting in Boston. Drug studies in children are important because children often respond differently to medications than adults. However, there is widespread concern about the lack of clinical evidence available to guide physicians in prescribing pharmaceuticals to children. Florence Bourgeois, MD, MPH, assistant professor at Harvard Medical School, and her colleagues sought to measure how much research activity is devoted to conditions representing a high burden of pediatric disease. They identified all drug trials for the 10 highest burden conditions registered from 2006 to 2011 in ClinicalTrials.

Researchers Urge More Patient-Centered Care For African-American Breast Cancer Survivors

African-American breast cancer survivors were satisfied with their cancer treatment, but most were never offered clinical trials opportunities or support services during or after their treatment, according to a study by a UC Davis Comprehensive Cancer Center researcher and her community partner, Rev. Tammie Dynse. The study, "The Unmet Needs of African-American Women with Breast Cancer, " involved interviews with 137 African-American women who survived breast cancer. Researchers sought to assess patients' clinical experiences, concerns and needs, asking participants questions about their treatment, access to information, support services and clinical trials, insurance and employment status, general health and lingering effects of cancer treatment. "Anyone who takes care of people with cancer should be aware of these concerns, " said Marlene M.

Flutemetamol For Alzheimer's - Phase 3 Results Released

According to GE Healthcare, the preliminary results of two Phase 3 studies of their investigational PET amyloid-imaging agent, [18F]flutemetamol, a GE Healthcare PET imaging agent developed to detect beta amyloid, both met their primary endpoints. Full results of both studies will be presented in the near future. One of the studies involved terminally ill patients, who agreed to undergo brain autopsy, displaying strong association between flutemetamol PET images and beta amyloid brain pathology linked to Alzheimer's disease (AD), whilst the other study was performed in young, healthy volunteers below the age of 40 years, and achieved similar results with the known lack of brain amyloid in this population. Carl Sadowsky, MD, Clinical Professor of Neurology at Nova Southeastern University Ft.

Warning Patients Of Impending Heart Attack Via Implantable Medical Device

More than 30% of the one million heart attack victims in the United States each year die before seeking medical attention. Although widespread education campaigns describe the warning signs of a heart attack, the average time from the onset of symptoms to arrival at the hospital has remained at 3 hours for more than 10 years. In their upcoming Ergonomics in Design article, "'This is your heart speaking. Call 911, '" authors Mary Carol Day and Christopher Young study the benefits of the AngelMed Guardian® , an implantable medical device currently undergoing clinical trials that alerts users about a potential heart attack through a combination of vibrations, audible tones, and visual warnings. What makes the device distinctive is this combination of alert modes. Although vibrotactile (vibrating) alarms are sometimes used to warn medical personnel in operating rooms or ICUs of an emergency, very little research has focused on their potential as a self-monitoring device for patients.

Significant Improvement In Disability Scores With Alemtuzumab

Genzyme presented additional data at the 64th Annual Meeting of the American Academy of Neurology from its Phase II CARE-MS II trial, which demonstrated that the Expanded Disability Status Scale (EDSS), i.e. a standard assessment of physical disability progression showed a considerably slower accumulation of disability in patients with multiple sclerosis (MS) who were treated with alemtuzumab, as compared with Rebif ® , a high dose subcutaneous interferon beta-1a. Furthermore, some patients who were treated with alemtuzumab from baseline registered a substantial improvement in disability scores, compared with those who received Rebif, which indicates a reversal of disability in these patients. Patients with pre-existing disability who were administered with alemtuzumab in the trial were more than double as likely to achieve a sustained reduction in disability compared with those who took Rebif.


Medical News © Nanda
Designer Damodar